Immuron Limited (IMRN): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMRN Stock Summary
- IMMURON LTD's market capitalization of $11,088,084 is ahead of just 4.63% of US-listed equities.
- For IMRN, its debt to operating expenses ratio is greater than that reported by only 0.44% of US equities we're observing.
- With a year-over-year growth in debt of -100%, IMMURON LTD's debt growth rate surpasses only 0% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to IMMURON LTD are MTLS, CMCM, CLRO, BKYI, and PHAR.
- IMRN's SEC filings can be seen here. And to visit IMMURON LTD's official web site, go to www.immuron.com.au.
IMRN Stock Price Chart Interactive Chart >
IMRN Price/Volume Stats
| Current price | $1.85 | 52-week high | $3.44 |
| Prev. close | $1.95 | 52-week low | $1.39 |
| Day low | $1.85 | Volume | 400 |
| Day high | $1.85 | Avg. volume | 13,268 |
| 50-day MA | $2.02 | Dividend yield | N/A |
| 200-day MA | $2.22 | Market Cap | 10.54M |
Immuron Limited (IMRN) Company Bio
Immuron Limited focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company was founded in 1994 and is based in Australia.
Latest IMRN News From Around the Web
Below are the latest news stories about IMMURON LTD that investors may wish to consider to help them evaluate IMRN as an investment opportunity.
Immuron First Half 2023 Earnings: AU$0.009 loss per share (vs AU$0.008 loss in 1H 2022)Immuron ( ASX:IMC ) First Half 2023 Results Key Financial Results Net loss: AU$1.98m (loss widened by 9.2% from 1H... |
Immuron CEO, Steven Lydeamore to host an investor webinarMELBOURNE, Australia, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, invites investors to join a live webcast hosted by Steven Lydeamore, CEO of Immuron Limited. Tuesday, 28 February 2023 at 11:00am Australian Eastern Standard Time (AEDT). To register in advance for this webinar, |
Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC TherapeuticMELBOURNE, Australia, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, today announces that a response letter has been submitted to the US Food and Drug Administration (FDA). Immuron has previously reported feedback was received from the FDA following a review of the Investigation |
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment MilestoneHighlights: First participants enrolled in USU Travelan Clinical Trial Field Study157 participants successfully randomized into the Clinical StudyPlans in place to enrol in 1302 healthy volunteers in total Infectious diarrhea is the most common illness reported by travelers & military personnel MELBOURNE, Australia, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially |
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated DiseaseMELBOURNE, Australia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that has been granted a European Patent for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease. Notification of the decision to g |
IMRN Price Returns
| 1-mo | -6.09% |
| 3-mo | -3.14% |
| 6-mo | -16.67% |
| 1-year | -44.11% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -11.06% |
| 2022 | -16.80% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Continue Researching IMRN
Want to see what other sources are saying about Immuron Ltd's financials and stock price? Try the links below:Immuron Ltd (IMRN) Stock Price | Nasdaq
Immuron Ltd (IMRN) Stock Quote, History and News - Yahoo Finance
Immuron Ltd (IMRN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...